Compare LZB & PGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LZB | PGEN |
|---|---|---|
| Founded | 1927 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Home Furnishings | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.4B | 1.4B |
| IPO Year | 1994 | 2013 |
| Metric | LZB | PGEN |
|---|---|---|
| Price | $35.79 | $4.24 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 1 | 5 |
| Target Price | ★ $39.00 | $8.33 |
| AVG Volume (30 Days) | 322.5K | ★ 2.7M |
| Earning Date | 06-16-2026 | 05-13-2026 |
| Dividend Yield | ★ 2.75% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 1.65 | N/A |
| Revenue | ★ $2,349,433,000.00 | $230,981,000.00 |
| Revenue This Year | $1.89 | $1,115.92 |
| Revenue Next Year | $2.09 | $81.04 |
| P/E Ratio | $21.48 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $29.03 | $1.26 |
| 52 Week High | $44.49 | $5.47 |
| Indicator | LZB | PGEN |
|---|---|---|
| Relative Strength Index (RSI) | 56.82 | 54.42 |
| Support Level | $35.32 | $4.12 |
| Resistance Level | $39.79 | $4.40 |
| Average True Range (ATR) | 0.90 | 0.20 |
| MACD | -0.02 | 0.01 |
| Stochastic Oscillator | 66.62 | 61.06 |
La-Z-Boy Inc is a U.S.-based company that manufactures, distributes, and retails upholstery furniture products. It is a producer of reclining chairs and distributors of residential furniture in the U.S. The company chiefly operates in the United States but also has secondary operations in Canada and other countries. The company's reportable segments include the Wholesale segment, which manufactures and imports upholstered furniture; Retail, which sells upholstered and case goods furniture to the end consumer and corporate and others. The majority of the company's revenue is derived from its Wholesale segment.
Precigen Inc is a commercial-stage biopharmaceutical company focused on developing precision medicines to improve the lives of patients, targeting immuno-oncology, autoimmune disorders, and infectious diseases using its proprietary and complementary technology platforms. These platforms support the development of gene programs, delivery through viral, non-viral, and microbe-based approaches, and control of gene expression for safety and efficacy. Its key platforms include AdenoVerse immunotherapy and UltraCAR-T, supported by the UltraPorator device for rapid and cost-effective manufacturing. Its clinical pipeline includes PRGN-2009, PRGN-3005, PRGN-3006, and PRGN-3007. Its reportable segments are Biopharmaceuticals and Exemplar.